December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Oncology Therapeutics, Inc. - Common Stock (NQ:BBOT)

2.120 +0.080 (+3.92%)
Delayed Quote Updated: 9:55 AM EST, Nov 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Oncology Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT to Participate in Upcoming December Investor Healthcare Conferences
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT to Participate in the Jefferies Global Healthcare Conference in London
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.